Literature DB >> 17994278

Inflammation and repair in viral hepatitis C.

Manuela G Neuman1, Kevin Sha, Rustan Esguerra, Sam Zakhari, Robert E Winkler, Nir Hilzenrat, Jonathan Wyse, Curtis L Cooper, Devanshi Seth, Mark D Gorrell, Paul S Haber, Geoffrey W McCaughan, Maria A Leo, Charles S Lieber, Mihai Voiculescu, Eugenia Buzatu, Camelia Ionescu, Jozsef Dudas, Bernhard Saile, Giuliano Ramadori.   

Abstract

Hepatitis C viral infection (HCV) results in liver damage leading to inflammation and fibrosis of the liver and increasing rates of hepatic decompensation and hepatocellular carcinoma (HCC). However, the host's immune response and viral determinants of liver disease progression are poorly understood. This review will address the determinants of liver injury in chronic HCV infection and the risk factors leading to rapid disease progression. We aim to better understand the factors that distinguish a relatively benign course of HCV from one with progression to cirrhosis. We will accomplish this task by discussion of three topics: (1) the role of cytokines in the adaptive immune response against the HCV infection; (2) the progression of fibrosis; and (3) the risk factors of co-morbidity with alcohol and human immunodeficiency virus (HIV) in HCV-infected individuals. Despite recent improvements in treating HCV infection using pegylated interferon alpha (PEGIFN-alpha) and ribavirin, about half of individuals infected with some genotypes, for example genotypes 1 and 4, will not respond to treatment or cannot be treated because of contraindications. This review will also aim to describe the importance of IFN-alpha-based therapies in HCV infection, ways of monitoring them, and associated complications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17994278     DOI: 10.1007/s10620-007-0047-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  187 in total

1.  Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.

Authors:  M S Sulkowski; D L Thomas; R E Chaisson; R D Moore
Journal:  JAMA       Date:  2000-01-05       Impact factor: 56.272

2.  DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy.

Authors:  Y Bourezane; D Salard; B Hoen; S Vandel; C Drobacheff; R Laurent
Journal:  Clin Infect Dis       Date:  1998-11       Impact factor: 9.079

3.  Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy.

Authors:  Manuela G Neuman; Jean-Pierre Benhamou; Marc Bourliere; Asma Ibrahim; Izabella Malkiewicz; Tarik Asselah; Michelle Martinot-Peignoux; Neil H Shear; Gady G Katz; Raoudha Akremi; Souad Benali; Nathalie Boyer; Laurence Lecomte; Veronique Le Breton; Gaelle Le Guludec; Patrick Marcellin
Journal:  Cytokine       Date:  2002-01-21       Impact factor: 3.861

4.  Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.

Authors:  Mark S Sulkowski; David L Thomas; Shruti H Mehta; Richard E Chaisson; Richard D Moore
Journal:  Hepatology       Date:  2002-01       Impact factor: 17.425

5.  Modelling how ribavirin improves interferon response rates in hepatitis C virus infection.

Authors:  Narendra M Dixit; Jennifer E Layden-Almer; Thomas J Layden; Alan S Perelson
Journal:  Nature       Date:  2004-12-16       Impact factor: 49.962

Review 6.  Mechanism of action of interferon and ribavirin in treatment of hepatitis C.

Authors:  Jordan J Feld; Jay H Hoofnagle
Journal:  Nature       Date:  2005-08-18       Impact factor: 49.962

7.  Consensus interferon induces peak mRNA accumulation at lower concentrations than interferon-alpha 2a.

Authors:  S B Klein; L M Blatt; M W Taylor
Journal:  J Interferon Res       Date:  1993-10

8.  Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

Authors:  Sharon Walmsley; Barry Bernstein; Martin King; José Arribas; Gildon Beall; Peter Ruane; Margaret Johnson; David Johnson; Richard Lalonde; Anthony Japour; Scott Brun; Eugene Sun
Journal:  N Engl J Med       Date:  2002-06-27       Impact factor: 91.245

Review 9.  The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host.

Authors:  Marius Braun; John M Vierling
Journal:  Liver Transpl       Date:  2003-11       Impact factor: 5.799

Review 10.  Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets.

Authors:  A M Gressner; R Weiskirchen
Journal:  J Cell Mol Med       Date:  2006 Jan-Mar       Impact factor: 5.310

View more
  16 in total

1.  Plasma levels of growth-related oncogene (CXCL1-3) associated with fibrosis and platelet counts in HCV-infected patients.

Authors:  S Johansson; W Talloen; M Tuefferd; J M Darling; A Scholliers; G Fanning; M W Fried; J Aerssens
Journal:  Aliment Pharmacol Ther       Date:  2015-08-28       Impact factor: 8.171

2.  Hepatic stimulator substance alleviates toxin-induced and immune-mediated liver injury and fibrosis in rats.

Authors:  Xuerui Yi; Ming Song; Youcheng Yuan; Xinrui Zhang; Wenyin Chen; Jin Li; Minghua Tong; Guangze Liu; Song You; Xiangping Kong
Journal:  Dig Dis Sci       Date:  2012-04-27       Impact factor: 3.199

3.  Inflammatory cytokines and mortality in a cohort of HIV-infected adults with alcohol problems.

Authors:  Daniel Fuster; Debbie M Cheng; Emily K Quinn; Kaku A Armah; Richard Saitz; Matthew S Freiberg; Jeffrey H Samet; Judith I Tsui
Journal:  AIDS       Date:  2014-04-24       Impact factor: 4.177

4.  Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems.

Authors:  Daniel Fuster; Debbie M Cheng; Emily K Quinn; David Nunes; Richard Saitz; Jeffrey H Samet; Judith I Tsui
Journal:  Addiction       Date:  2013-10-24       Impact factor: 6.526

5.  Specific oligopeptides in fermented soybean extract inhibit NF-κB-dependent iNOS and cytokine induction by toll-like receptor ligands.

Authors:  Woo Hyung Lee; Hong Min Wu; Chan Gyu Lee; Dae Il Sung; Hye Jung Song; Toshiro Matsui; Han Bok Kim; Sang Geon Kim
Journal:  J Med Food       Date:  2014-09-03       Impact factor: 2.786

6.  Pegylated interferon de novo-induce autoimmune haemolytic anaemia in chronic hepatitis C patient.

Authors:  Ashraf Said; Ashraf Elbahrawy; Mohamed Alfiomy; Mohamed Abdellah; Khaled Shahat; Mohamed Salah; Sadek Mostafa; Ahmed Elwassief; Attef Aboelfotoh; Hafez Abdelhafeez; Assem El-Sherif
Journal:  BMJ Case Rep       Date:  2011-08-11

Review 7.  Microbial translocation across the GI tract.

Authors:  Jason M Brenchley; Daniel C Douek
Journal:  Annu Rev Immunol       Date:  2012-01-03       Impact factor: 28.527

8.  Alcoholic liver disease: a synopsis of the Charles Lieber's Memorial Symposia 2009-2012.

Authors:  Manuela G Neuman; Lawrence Cohen; Samir Zakhari; Radu M Nanau; Sebastian Mueller; Michelle Schneider; Charles Parry; Romina Isip; Helmut K Seitz
Journal:  Alcohol Alcohol       Date:  2014-05-09       Impact factor: 2.826

9.  Interleukin-6 is associated with noninvasive markers of liver fibrosis in HIV-infected patients with alcohol problems.

Authors:  Daniel Fuster; Judith I Tsui; Debbie M Cheng; Emily K Quinn; Kaku A Armah; David Nunes; Matthew S Freiberg; Jeffrey H Samet
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05-17       Impact factor: 2.205

Review 10.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.